Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Daijiro Harada"'
Autor:
Naofumi Hara, Takuo Shibayama, Yoshinobu Maeda, Katsuyuki Kiura, Shingo Harita, Daizo Kishino, Daijiro Harada, Eiki Ichihara, Nobuaki Ochi, Katsuyuki Hotta, Koji Inoue, Shinobu Hosokawa, Nagio Takigawa, Naohiro Oda
Publikováno v:
European Journal of Cancer. 149:73-81
Background Immune checkpoint inhibitors (ICIs) are essential for treatment of various malignancies, including non–small-cell lung cancer (NSCLC). Recently, several studies have shown that the gut microbiome plays an important role in ICI treatment
Autor:
Daijiro Harada, Hideko Isozaki, Toshiyuki Kozuki, Toshihide Yokoyama, Hiroshige Yoshioka, Akihiro Bessho, Shinobu Hosokawa, Ichiro Takata, Nagio Takigawa, Katsuyuki Hotta, Katsuyuki Kiura, Okayama Lung Cancer Study Group
Publikováno v:
Thoracic Cancer, Vol 12, Iss 5, Pp 643-649 (2021)
Thoracic Cancer
Thoracic Cancer
Background The efficacy of crizotinib treatment for recurring EML4‐ALK‐positive non‐small cell lung cancer (NSCLC) previously treated with alectinib is unclear. Based on our preclinical findings regarding hepatocyte growth factor/mesenchymal ep
Autor:
Katsuyuki Kiura, Takuya Fukazawa, Daijiro Harada, Masami Takeyama, Hiromichi Yamane, Tomoko Ikeda, Noriko Miyake, Nobuaki Ochi, Nagio Takigawa, Nozomu Nakagawa, Etsuko Yokota, Hidekazu Nakanishi, Yasunari Nagasaki
Publikováno v:
Experimental cell research. 409(2)
Lung cancer that exhibits epidermal growth factor receptor (EGFR) gene mutation is sensitive to EGFR-tyrosine kinase inhibitors (TKIs), such as osimertinib. Receptor tyrosine kinase-like orphan receptor 1 (ROR1) may be involved in overcoming EGFR-TKI
Autor:
Naoyuki Nogami, Toshio Kubo, Kadoaki Ohashi, Nobuaki Fukamatsu, Katsuyuki Kiura, Toshiyuki Kozuki, Daijiro Harada, Akihiro Bessho, Shinobu Hosokawa, Masayuki Yasugi, Hiroshige Yoshioka, Katsuyuki Hotta, Toshihide Yokoyama, Shoichi Kuyama, Isao Oze, Nagio Takigawa, Kenichiro Kudo, Naoyuki Sone
Publikováno v:
Asia-Pacific Journal of Clinical Oncology
Aim We investigated the efficacy, safety and optimal schedule of nanoparticle albumin‐bound paclitaxel monotherapy as second‐ or third‐line treatment for non‐small‐cell lung cancer patients without epidermal growth factor receptor mutation
Autor:
Takuo Shibayama, Yoshinobu Maeda, Shingo Harita, Naofumi Hara, Koji Inoue, Shinobu Hosokawa, Eiki Ichihara, Akihiro Bessho, Katsuyuki Kiura, Naohiro Oda, Katsuyuki Hotta, Daizo Kishino, Daijiro Harada, Nobuaki Ochi
Publikováno v:
Japanese journal of clinical oncology. 51(2)
Objectives Studies investigating the association between radiation therapy and the efficacy of immune checkpoint inhibitors in advanced non-small-cell lung cancer have provided inconsistent results, likely due to relatively small cohort sizes. This s
Autor:
Daizo Kishino, Naofumi Hara, Katsuyuki Kiura, Daijiro Harada, Hirohisa Kano, Eiki Ichihara, Katsuyuki Hotta, Koji Inoue, Kiichiro Ninomiya, Shinobu Hosokawa, Hiroe Kayatani, Nobuaki Ochi, Naohiro Oda, Yoshinobu Maeda, Kazuhiko Watanabe
Publikováno v:
Cancer Science
Most clinical trials of non‐small‐cell lung cancer (NSCLC) exclude patients with poor ECOG performance status (PS). Thus, the efficacy of immune checkpoint inhibitors (ICIs) in patients with poor PS remains unclear. Herein, we used data from a re
Autor:
Shingo Harita, Takuo Shibayama, Eiki Ichihara, Nobuaki Ochi, Katsuyuki Kiura, Yoshinobu Maeda, Daijiro Harada, Naohiro Oda, Koji Inoue, Shinobu Hosokawa, Katsuyuki Hotta, Daizo Kishino, Naofumi Hara
Publikováno v:
Cancer immunology, immunotherapy : CII. 70(1)
Immune checkpoint inhibitors (ICIs) are less effective in non-small-cell lung cancer (NSCLC) patients with epidermal growth factor receptor (EGFR) mutations. However, a small percentage of patients with EGFR-mutant NSCLC do respond, and the character
Autor:
Kazuhiko Watanabe, Eiki Ichihara, Naofumi Hara, Nobuaki Ochi, Ken Sato, Daizo Kishino, Katsuyuki Kiura, Katsuyuki Hotta, Daijiro Harada, Yoshinobu Maeda, Naohiro Oda, Koji Inoue, Shinobu Hosokawa
Publikováno v:
Lung cancer (Amsterdam, Netherlands). 139
Objectives : Body mass index (BMI) is reported to be associated with the efficacy of immune checkpoint inhibitors (ICIs) in solid tumors such as melanomas. However, it remains unclear whether such a relationship exists in non-small cell lung cancer (
Autor:
Takuo Shibayama, Koji Inoue, Shingo Harita, Shoichi Kuyama, Katsuyuki Hotta, Masaaki Inoue, Daisuke Minami, Hirohisa Ichikawa, Takashi Ninomiya, Toshio Kubo, Daizo Kishino, Naohiro Oda, Nagio Takigawa, Toshi Murakami, Toshihide Yokoyama, Katsuyuki Kiura, Daijiro Harada, Eiki Ichihara, Kiichiro Ninomiya, Mitsune Tanimoto
Publikováno v:
Clinical Lung Cancer. 18:241-244
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) as first-line therapy for patients with EGFR-mutated non-small-cell lung cancer (NSCLC) have shown a significantly better objective response rate and progression-free survival
Autor:
Kazuto Nishio, Takayasu Kurata, Takayuki Shimose, Koichi Azuma, Yoichi Nakanishi, Kazuko Sakai, Isamu Okamoto, Hiroaki Akamatsu, Katsuyuki Hotta, Junji Kishimoto, Kaname Nosaki, Daijiro Harada, Tatsuro Fukuhara, Koichi Goto, Fumiyoshi Ohyanagi, Taishi Harada, Eiji Iwama
Publikováno v:
Annals of Oncology. 28:136-141
Analysis of circulating cell-free DNA (cfDNA) is under intensive investigation for its potential to identify tumor somatic mutations. We have now explored the usefulness of such liquid biopsy testing with both the digital polymerase chain reaction (d